Regulatory News
Friday, May 20, 2016
UPDATE 2-FDA staff question utility, trials of Novo Nordisk diabetes drug
May 20 (Reuters) - A preliminary review by the U.S. Food and
Drug Administration of Novo Nordisk A/S's experimental
diabetes drug, IDegLira, questioned the interpretability of the
study findings and...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment